Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

Conditions: Pathway Mutant Myelodysplastic Syndromes; Myelodysplastic Neoplasm; Myeloproliferative Neoplasm Interventions: Drug: ASTX029; Drug: ASTX727 Sponsors: M.D. Anderson Cancer Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials